PolyPid to Present at the JMP Securities 2022 Life Sciences Conference

Rhea-AI Summary

PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company, will present at the JMP Securities 2022 Life Sciences Conference in New York City on June 15-16, 2022. The presentation is scheduled for June 15 at 11:00 AM Eastern Time. PolyPid focuses on improving surgical outcomes through its proprietary PLEX technology, which allows controlled, prolonged release of therapeutics. The lead product candidate, D-PLEX100, is currently in Phase 3 trials targeting surgical site infections. For inquiries, investors can reach out to their JMP representatives.

PETACH TIKVA, Israel, June 02, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will present at the JMP Securities 2022 Life Sciences Conference, which is being held in New York City, on June 15-16, 2022.

JMP Securities 2022 Life Sciences Conference:
Presentation Date:	Wednesday, June 15, 2022
Presentation Time:	11:00 AM Eastern Time

Investors interested in meeting with PolyPid during the conference should contact their JMP representative.

About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX₁₀₀ is in Phase 3 clinical trials for the prevention of soft tissue abdominal and sternal bone surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma. For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.

References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.

Contacts: 
PolyPid Ltd. 
Dikla Czaczkes Akselbrad
EVP & CFO
Tel: +972-747195700

Investors:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com

Media Contact:
Nechama Feuerstein
551-444-0784
Nechama.Feuerstein@finnpartners.com

FAQ

When is PolyPid presenting at the JMP Securities 2022 Life Sciences Conference?

PolyPid will present at the JMP Securities 2022 Life Sciences Conference on June 15, 2022, at 11:00 AM Eastern Time.

What is the focus of PolyPid's presentation at the conference?

PolyPid's presentation will focus on its efforts to improve surgical outcomes through its proprietary PLEX technology.

What is the stock symbol for PolyPid?

The stock symbol for PolyPid is PYPD.

What is D-PLEX100 in relation to PolyPid?

D-PLEX100 is PolyPid's lead product candidate currently in Phase 3 clinical trials for preventing surgical site infections.

Where can I find more information about PolyPid and their products?

More information about PolyPid and its products can be found on their official website at www.polypid.com.